Compare TV & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | OCS |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | Mexico | Switzerland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1993 | N/A |
| Metric | TV | OCS |
|---|---|---|
| Price | $3.31 | $28.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.93 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 1.1M | 336.1K |
| Earning Date | 02-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,246,959,081.00 | $991,999.00 |
| Revenue This Year | N/A | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $14.00 |
| 52 Week High | $3.48 | $29.36 |
| Indicator | TV | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 65.31 |
| Support Level | $3.05 | $27.30 |
| Resistance Level | $3.45 | $29.10 |
| Average True Range (ATR) | 0.12 | 1.25 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 64.87 | 74.19 |
Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.